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Purpose: We hypothesised that varying native oocyte-secreted factor (OSF) 25 
exposure or using different recombinant OSF peptides would have differential 
effects on post-in vitro maturation (IVM) embryo and fetal development.  
Methods: Mouse cumulus oocyte complexes (COCs) were treated with the 
purified mature domain of GDF9 and/or BMP15 or were co-cultured with 
denuded oocytes (DOs) from 0h or 3h of IVM. DOs were matured for 3h as 30 
either intact COCs+/-FSH before denuding, or as DOs+FSH. COCs were 
fertilised and blastocyst development was assessed on days 5 and 6, and  
either differentially stained for ICM numbers or vitrified/warmed embryos were 
transferred to recipients to assess implantation and fetal rates.  
Results: No improvement in embryo development was observed with the 35 
addition of GDF9 and/or BMP15 to IVM. In contrast, embryos derived from 
COCs co-cultured with DOs had significantly improved blastocyst rates and 
ICM numbers compared to controls (P < 0.05). The highest response was 
obtained when DOs were first added to COCs at 3h of IVM, after being pre-
treated (0-3h) as COCs+FSH. Compared to control, co-culture with DOs from 40 
3h did not affect implantation rates but more than doubled fetal yield (21% vs 
48%; P < 0.05). GDF9 Western blot analysis was unable to detect any 
differences in quantity or form of GDF9 (17 and 65 kDa) in extracts of DO at 
0h or 3h. 
Conclusions: This study provides new knowledge on means to improve 45 
oocyte quality in vitro which has the potential to significantly aid human 
infertility treatment and animal embryo production technologies.  
 Introduction 
 50 
In vitro maturation (IVM) of oocytes is an alternative system used in assisted 
reproductive technology for generating embryos in vitro, which reduces or 
eliminates the need to administer gonadotrophins to patients. In addition, IVM 
is widely used in the domestic animal sector to further advanced-breeding 
technologies. However, there is a discrepancy in the success rate of 55 
conventional in vitro matured oocytes compared to in vivo matured oocytes. In 
women, it is reported that the pregnancy rate post-IVM is less than half of the 
pregnancy rate post-IVF (in vitro fertilisation) [1]. To overcome this challenge, 
it is important to understand factors that regulate the maturation and 
development of oocytes which can be implemented in clinical and veterinary 60 
scenarios to improve the success rate of IVM [2].   
Oocytes acquire developmental competence in the ovarian follicle. 
There are numerous molecules, proteins and cellular processes involved in 
the bi-directional communication axis between the oocyte and follicular 
somatic cells [3]. The oocyte regulates this communication network to a 65 
significant degree. The oocyte secretes soluble factors (OSFs) which are 
transmitted to cumulus cells via paracrine signalling to regulate a multitude of 
important cumulus cell processes, including; proliferation [4, 5], apoptosis [6], 
differentiation [7], luteinisation [8], metabolism [9-12] and expansion [13, 14].  
Another type of communication between the oocyte and cumulus cells is via 70 
gap junctional signalling, mediated by cumulus trans-zonal cytoplasmic 
projections that abut the oocyte membrane, enabling transport of cAMP, 
purines/pyrimidines, amino acids and other small regulatory molecules [15-
18]. Cumulus cells provide signals and molecules to the oocyte to regulate 
meiosis and promote developmental competence [19, 20]. Removal of 75 
cumulus cells during maturation has a significant detrimental effect on nuclear 
maturation, normal fertilization and developmental competence of oocytes [21, 
22]. Follicle-stimulating hormone (FSH) is typically added to IVM medium to 
stimulate cumulus expansion [17] and increase normal fertilization rates and 
fetal development of IVM oocytes [23, 24].  80 
 
Growth differentiation factor-9 (GDF9) and bone morphogenetic 
protein-15 (BMP15) are two well-known soluble growth factors derived from 
oocytes that are important for normal cumulus cell function and hence normal 
oocyte development [19]. In mouse oocytes, the expression level of GDF9 85 
mRNA is much higher compared to BMP15 [25], reflecting the relative 
importance of their roles in folliculogenesis. Homozygous GDF9 mutant mice 
are sterile due to a block in follicular development beyond the primary follicle 
stage [26], whereas BMP15 null mice demonstrate only a mild reduction in 
ovulation and fertilization rates [27]. Homozgous GDF9 or BMP15 mutant 90 
sheep derived either by natural mutation or active immunization are sterile, 
however, heterozygous carriers of mutations in either GDF9 or BMP15 have 
an increased ovulation rate and multiple pregnancies [28-30]. GDF9 and 
BMP15 also play an important role in human fertility, where several mutations 
of GDF9 may be potentially associated with  polycystic ovary syndrome [31] 95 
and rare variants of GDF9 contribute to dizygotic twinning [32]. Moreover, rare 
mutations of GDF9 and BMP15 are associated with premature ovarian failure 
[33-35].   
GDF9 and BMP15 in the proteolytically processed form consist of two 
structural parts: the pro-region and the mature region [36]. GDF9 and BMP15 100 
are processed and secreted as non-covalent complexes of the pro- and 
mature regions, the mature region being the bioactive receptor binding region, 
whereby the pro-region plays a vital and species-specific role in regulating 
bioactivity [37-39]. Immunizing mice against the pro-regions of GDF9 or 
BMP15 caused ovary abnormalities and smaller litter sizes [40].   105 
However, the exact forms of GDF9 and BMP15 secreted by oocytes in 
vivo and in vitro are unclear. Mouse in vitro matured oocytes secrete GDF9 as 
a mixture of the unprocessed pro-protein and mature domain [41]. Rat IVM 
oocytes secrete the mature domains of GDF9 and BMP15 [42]. Sheep 
follicular fluid contains GDF9 and BMP15 proteins in the unprocessed pro-110 
protein form only [43], whereas sheep oocytes secrete the mature domains of 
GDF9 and BMP15 during IVM [42]. To our knowledge, the only commercially 
available forms of GDF9 and BMP15 produced in a  recombinant mammalian 
cell expression system are from R&D Systems and these consist of purified  
mature domains only.  115 
IVM COCs have abberant gene expression and altered matrix protein 
profiles in cumulus cells compared to in vivo matured oocytes [44], and in vitro 
matured oocytes also have notably decreased expression of BMP15 
compared to in vivo matured oocytes (Gilchrist et al., unpublished). Currently, 
studies show that addition of exogenous native OSFs during IVM significantly 120 
improves subsequent goat [45], cow [20, 46, 47] and pig [48] embryo 
development, and recombinant GDF9 and BMP15 in their pro-mature form 
improve in vitro matured cattle [12, 46, 47] and mouse oocytes [49]. In 
addition, differing degrees of improved bovine oocyte competence were 
observed depending on the temporal pattern of addition of OSFs during IVM 125 
[46]. The current study explores in more detail the effects of different forms of 
OSFs added during IVM on oocyte developmental competence.  We examine 
the effects of commercially available forms of recombinant GDF9 and BMP15 
and of native OSFs. We also explore factors that affect the production of 
native OSFs by mouse oocytes, such as the timing of addition of denuded 130 
oocytes (DOs) and the presence of cumulus cells and FSH before denuding 
COCs and addition to IVM. Outcomes examined were embryo development, 
cryotolerance of blastocysts and fetal measures following embryo transfer.  
 
Materials and Methods 135 
 
All chemicals and media were purchased from Sigma Chemical (St Louis, 
MO, USA) unless indicated otherwise.  
 
Isolation and maturation of COCs 140 
Mice used in this study were maintained in the Animal House, Medical School, 
University of Adelaide. This study was approved by the local animal ethics 
committee and conducted in accordance with the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes.  
Twenty-one to twenty-eight day-old SV129 mice were injected 145 
intraperitoneally with 5 IU equine chorionic gonadotrophin (eCG; Folligon, 
Intervet, Castle Hill, Australia), and ovaries were collected 46-48 hours (h) 
later. Ovaries were cleaned of any connective tissues and placed in HEPES-
buffered αMEM (handling medium, GIBCO, USA) supplemented with 3 mg/ml 
fatty-acid free bovine serum albumin (FAF BSA, MP Biomedicals, USA), 1 150 
mg/ml fetuin and 50 µmol 3-isobutyl-1-methylxanthine (IBMX). All antral 
follicles were punctured with 27-gauge needles and immature COCs collected 
in handling medium, then washed twice with handling medium minus IBMX. 
Only COCs with compact cumulus cells (CCs) were taken. The rationale 
behind the use of IBMX was to maintain all COCs in the same nuclear stage 155 
before transfer into maturation medium or being denuded. For the control 
group, 20 COCs were cultured in 50 µl IVM drops [(αMEM supplemented with 
3 mg/ml FAF BSA, 1 mg/ml fetuin and 50 mIU/ml FSH (Puregon, Organon, 
Oss, Netherlands)] overlaid with mineral oil in 60 mm Petri dishes (Falcon, 
Becton Dickinson, USA) for 17-18 h at 370C in a humidified atmosphere of 5% 160 
CO2 in air. For treatment groups, 20 COCs were cultured with 50 DOs in 50 µl 
IVM drops (1 DO/µl). In addition, the effect of exogenous recombinant human 
BMP15 (Catalogue No: 739-G9, R&D Systems, Minnaepolis, MN, USA) and 
recombinant mouse GDF9 (Catalogue No: 5096-BM, R&D Systems) in mouse 
IVM was examined. Both of these growth factors are supplied as homodimers 165 
of the mature region. COCs were exposed to graded doses (50 ng/ml, 100 
ng/ml, and 200 ng/ml) of exogenous BMP15 and GDF9, as well as a 
combination of both proteins.  
 
Generation of denuded oocytes as a source of native OSFs 170 
DOs were generated by vortexing COCs for ~2 minutes in αMEM handling 
medium in order to remove the CC. 
There were then a number of different processing methods used to produce 
native OSFs before co-culture with immature COCs (see Table 1 and Fig. 1): 
1. COCs were denuded at 0 h before co-culture of 50 DOs with 20 COCs 175 
in IVM medium containing FSH. For COCs+DOs, IBMX was not 
present in the handling medium, and therefore >90% of DOs were at 
the GVBD stage. This group was utilized to assess the benefits of DOs 
as a source of native OSFs and will be referred to as COCs+DOs. By 
contrast, for COCs+DOs (0h [GV]), IBMX was present in the handling 180 
medium and therefore these DOs were at the GV stage.  
2. COCs were matured first for 3 h in separate IVM medium containing 
FSH. After 3 h of IVM, COCs were denuded and 50 DOs were co-
cultured with 20 COCs for another 14-15 h in IVM medium containing 
FSH (Fig. 1a). This group is based on the design by Hussein et al 185 
(2011), and was utilized to examine temporal, cumulus cell and FSH 
effects on the production of native OSFs. This group is referred to as 
COCs+DOs at 3h+FSH+CC.  
3. Intact COCs were matured first for 3 h in separate IVM medium without 
FSH (Fig. 1b). After 3 h of IVM, COCs were denuded and 50 DOs were 190 
co-cultured with 20 COCs for another 14-15 h in IVM medium 
containing FSH. This group assessed the production of native OSFs in 
the absence of FSH during the first 3 h of maturation and is referred to 
as COCs+DOs at 3h-FSH+CC.  
4. COCs were denuded at 0 h and then matured for 3 h as DOs in 195 
separate IVM medium containing FSH, 50 of these DOs were co-
cultured with 20 COCs for another 14-15 h in IVM medium containing 
FSH (Fig. 1c). This group is referred to as COCs+DOs at 3h+FSH-CC 
and was designed to assess the effect of CCs on production of native 
OSFs.   200 
 
Oocyte nuclear maturation 
An experiment was performed to assess whether adding native OSFs affects 
the timing of oocyte nuclear maturation. At 12 h and 15 h of IVM, COCs were 
denuded and fixed in paraformaldehyde for 30 minutes, then stained with 205 
DAPI. The presence of the first polar body was determined using an upright 
microscope (Nikon, TE 2000-E) under UV light.   
 
In vitro fertilization  
Sperm from  CBA F1 male mice aged 6-24 weeks and of proven fertility were 210 
incubated for 1 hour in IVF medium (COOK® IVF, Research medium, 
Catalogue No: K-RVWA- 50, Australia) under 5% CO2 at 37
0C for 
capacitation.  Post-IVM, COCs were transferred into a 90 µl equilibrated IVF 
drop overlayed with mineral oil and then 10 µl of capacitated sperm were 
added into the drops. Three hours post-fertilization under 5% CO2 at 37
0C, the 215 
presumptive zygotes were denuded of sperm and cumulus cells. Insemination 
day was counted as day 1 (0 h).  
 In vitro culture of embryos 
Five to ten presumptive zygotes were cultured in 20 µl drops of equilibrated 220 
culture media (COOK® IVC, Research medium, Catalogue No: K-RVCL-50, 
Australia) overlayed with mineral oil under 6% CO2, 5% O2 and 89% N2 
atmosphere. Embryos were cultured for six days, with cleavage rates 
assessed on day 2 (24 h post-fertilization) and blastocysts assessed on day 5 
(96-100 h post-fertilization) and day 6 (120-24 h post-fertilization).  225 
 
Differential staining of blastocysts 
Differential staining was performed on day 6 blastocysts to assess inner cell 
mass (ICM) and trophectoderm (TE) cell. Briefly, expanded, hatching and 
hatched blastocysts were placed into pronase (5 mg/ml) at 370C until the zona 230 
dissolved. The zona-free blastocysts were incubated in 10 mM trinitrobenzene 
sulfonic acid (TNBS) in 0.4% polyvinyl alchol (PVA) in phosphate-buffered 
saline (PBS) at 40C for 10 minutes then washed twice before being 
transferred into 0.1 mg/ml anti dinitrophenol-BSA antibody at 370C for 10 
minutes. Embryos were then incubated in 10 µg/ml propidium iodide for 5-10 235 
minutes at 370C, followed by 4 µg/ml Hoechst 33342 in 96% ethanol at 40C 
overnight. The blastocysts were transferred onto a glass microscope side, 
covered by a cover slip and assessed immediately under UV fluorescence 
using an upright microscope (Nikon, TE 2000-E, excitation, 340-380 nm; 
emission, 440-480 nm), where ICM cells appeared blue and TE cells 240 
appeared pink.   
 
Vitrification and warming of blastocysts 
Hatching and expanded blastocysts on day 6 were vitrified and then within 1-2 
weeks those blastocysts were warmed and assessed for cryotolerance, prior 245 
to embryo transfer. Vitrification and warming solutions were prepared in 
HEPES-buffered αMEM. The vitrification solution consisted of 2.3 M 
dimethylsulfoxide (DMSO) + 3 M ethylene glycol supplemented with 0.75 M 
sucrose. The corresponding equilibration solution contained half the 
concentration of cryoprotectants of the vitrification solution and no sucrose.  250 
Vitrification steps were performed at 370C. Blastocysts were placed in 
equilibration solution for 3 minutes then transferred to vitrification solution, 
with minimal transfer of equilibration solution (less than 3 µl), placed on a 
fibre-plugTM (CVM kit, Cryologic, Victoria, Australia) and touched on a pre-
cooled steel block in liquid nitrogen, and then sealed in a pre-cooled straw 255 
(CVM kit, Cryologic) for storage in liquid nitrogen. The time taken from leaving 
equilibration solution to vitrification on the block was 30 - 40 sec. Vitrified 
blastocysts were warmed at 370C and sequentially passed through 3 solutions 
of sucrose (0.3 M, 0.25 M and 0.15 M) in HEPES-buffered αMEM for 5 
minutes each. Blastocysts were held in culture medium for 2-3 h and then 260 
blastocyst morphology was assessed before being transferred into foster 
mothers. The criteria used for blastocyst cryosurvival were as follows [50]; 
normal: blastocysts expanded with no signs of lysis, collapse or degeneration; 
abnormal: blastocysts with signs of lysis, collapse and degeneration. 
 265 
Embryo transfer and assessment of fetal outcomes  
Vitrified/warmed blastocysts assessed as normal were transferred into 
pseudopregnant recipients (Swiss female mice aged 12-20 weeks, mated with 
vasectomised F1 CBA males). On day 3.5 of pseudopregnancy, recipients 
were anaesthetized with 2% Avertin (0.015 ml/g body weight) prior to embryo 270 
transfer. For each recipient, six normal expanded or hatching blastocysts 
post-vitrification/warming were transferred to each uterine horn, with control 
embryos in one horn and treatment embryos in the other. Eight replicates 
were performed with a total of 96 blastocysts transferred into 8 recipients. The 
number of implantation sites, fetuses, fetal and placental weights and fetal 275 
crown to rump lengths were assessed on day 17 post-embryo transfer.  
 
Immunodetection of oocyte GDF9  
DOs and oocyte-conditioned media were collected for western blot analysis of 
the form and quantity of GDF9 protein. Briefly, COCs were collected and 280 
denuded at 0 h and suspended at a ratio of 8 DOs/µl in IVM medium in 
Eppendorf tubes. DOs were matured for 17-18 h under 5% CO2 at 37
0C. Post-
IVM, DOs were pelleted by centrifugation and oocyte-conditioned medium 
was transferred to a separate tube and snap frozen in PBS. Oocytes were 
washed once in PBS, after which the PBS was removed and the cells snap 285 
frozen. Oocytes and oocyte-conditioned medium were also collected from the 
3h+FSH+CC group (Fig. 1a). COCs were matured first for 3 h in IVM medium, 
then denuded and matured for an extra 14-15 h in fresh IVM medium. Post-
IVM, oocytes and oocyte-conditioned medium were processed as above. 
Samples (30-60 DOs or media equivalent) were boiled for 3 minutes in 1xLDS 290 
reducing buffer [15ul, 1 x Novex NuPAGE LDS sample buffer (NP0009)] with 
mercaptoethanol (Novex NuPAGE NP0007, Carlsbad, USA) and centrifuged. 
The supernatant was fractionated by SDS-PAGE for 1 h at RT on 4-12% Bis-
Tris pre-cast gel (BioRad, Hercules, Ca, USA, Cat#345-0125) in MES buffer 
(Novex, NuPAGE, NP0002) followed by electrotransfer at 30V overnight at 295 
4°C onto a nitrocellulose membrane (Hybond-C Extra, GE Healthcare Life 
Sciences, Bucks, UK). The membrane was incubated with biotinylated GDF9- 
monoclonal antibody 53 (Oxford Brookes University, Oxford, UK) at 1:2,000 
for 1hr at RT then washed, followed by a further incubation with horseradish 
peroxidase-conjugated anti-mouse IgG (SNN2004, Lot No 892329B, 300 
Biosource), at 1:10,000 for 1 h at RT. Immunoreactive proteins were detected 
using Lumilight chemiluminesence reagents (Roche Diagnostics, 
GmbH Mannheim, Germany). Membranes were scanned on the BioRad 
ChemiDoc MP system and the images analysed using Image J software 
(Biorad).  Recombinant mGDF9 (17k) was used as a reference protein. 305 
Biotinylated molecular wt protein standards (Cat No. MW001) were obtained 
from R&D Systems, (Minneapolis, USA). Parallel controls (blanks) were 
undertaken with oocyte extracts in the absence of biotinylated antibody but in 
the presence of HRP-IgG antibody. 
 310 
Statistical analyses 
All proportional data for embryo development were arcsine transformed and 
analysed using either an independent t-test or multivariate ANOVA with least 
significant difference (LSD) post-hoc tests. Log transformation was performed 
for blastocyst cell number when data were not normally distributed, and 315 
analysed using an independent t-test or one way ANOVA with either LSD or 
Dunnet’s T3 post-hoc tests, depending on whether the data did or did not 
pass the homogeneity of variance test, respectively. Fetal measurements 
were analysed with independent t-tests with LSD post-hoc tests. Oocyte 
nuclear maturation, survival rate post-warming of blastocysts and post-embryo 320 
transfer data for fetal survival and implantation rates were assessed using a 
Chi-square test. All statistical analyses were performed using SPSS version 
13 (SPSS Inc, Chicago, IL, USA). Differences were considered statistically 




Effect of co-culture of intact mouse COCs with native OSFs during IVM  
Exposure of intact COCs to exogenous native OSFs from DOs throughout 
IVM significantly (P < 0.05) increased the cleavage rate compared to COCs 330 
cultured alone. ICM cell numbers were also significantly increased in 
blastocysts derived from COCs exposed to DOs, whereas TE and total cell 
numbers were not affected (Table 2).  
 
Effect of mature form of GDF9 and BMP15 (R&D Systems) on mouse 335 
oocyte developmental competence 
In contrast to the effect of native OSFs, improvements in embryo development 
were not observed with the addition of mature domain GDF9 (Table 3) or 
mature BMP15 (Table 4) to IVM medium at 50 ng/ml, 100 ng/ml or 200 ng/ml, 
or a combination of both proteins at the same doses (Table 5).  340 
 
Temporal effect of co-culture of intact mouse COCs with native OSFs 
during IVM  
A previous study by [46] demonstrated that there is a temporal effect of native 
OSFs on bovine oocyte developmental competence. Based on this result, we 345 
assessed mouse oocyte developmental competence following co-culture of 
COCs with DOs in a temporal manner. COCs were co-cultured with DOs from 
0 h (0h [GV] stage) or with DOs precultured as COCs for 3h+FSH+CC (refer 
to Fig. 1a).  Following co-culture of COCs with DOs from 0-17 h (0h [GV] 
stage), a significant increase was observed in cleavage rate compared to 350 
controls, however there were no significant differences in blastocyst rates or 
ICM number (Table 6). By contrast, treating COCs with DOs from 3h 
(3h+FSH+CC) significantly (P < 0.05) increased blastocyst and hatching 
blastocyst rates measured at day 6 and subsequent ICM cell numbers, 
compared to the control group.  355 
 
Effect of exposure of COCs to native OSFs on nuclear maturation  
Native OSFs regulate CC cGMP levels [51] which affects meiosis and, 
according to [20], co-culture of COCs with DOs increased nuclear maturation 
rate in bovine oocytes.  Since the highest competence treatment group from 360 
the previous experiment was COCs co-cultured with DOs from 3h 
(3h+FSH+CC), we hypothesised that an effect on oocyte nuclear maturation 
could account for this enhanced oocyte quality in mice. However, in the 
present experiment, there was no significant difference in the maturation rates 
of control oocytes or COCs exposed to DOs (3h+FSH+CC) at 12h or 15h of 365 
IVM (Table 7). 
 
Temporal effects on oocyte GDF9 levels 
Given the beneficial effects of pre-culture of oocytes with their CCs for 3 h 
with FSH on OSF-stimulated oocyte developmental competence (Table 6), it 370 
was attempted to quantify the amount and form of GDF9 expressed within and 
secreted by oocytes. The band for the un-processed pro-protein was 
observed at ~65 kDa and the mature protein at ~17 kDa, with the mature 
protein less abundant in oocyte extracts (Fig. 2). Three hours of pre-culture 
(3h+FSH+CC) had no effect on the total quantity or the proportion of pro- 375 
versus mature-GDF9 in oocytes. No GDF9 bands were observed in the DO 
conditioned media.  
 
The role of FSH and cumulus cells in the production of native OSFs  
We hypothesized that FSH and cumulus cells are two factors that affect the 380 
production of native OSFs. In this experiment, DOs were generated using 
different methods (see Fig. 1).  Following co-culture of COCs with precultured 
DOs (3h+FSH+CC; see Fig. 1a), a significantly increased blastocyst rate on 
day 5 was observed compared to control, which contributed to an 
improvement in ICM number compared to control (Table 8). DOs that were 385 
pre-cultured as intact COCs but without FSH (3h-FSH+CC, Fig. 1b) did not 
stimulate developmental competence in their co-cultured COCs; these 
exhibited embryo developmental parameters equivalent to the control and 
ICM numbers significantly lower than those stimulated with FSH 
(3h+FSH+CC). Interestingly, there was a significant improvement in blastocyst 390 
rate on day 6 from COCs co-cultured with DOs that were without CCs from 0-
3h (3h+FSH-CC, see Fig. 1c) compared to the control. Overall, all treatment 
groups co-cultured with DOs tended to show an improvement in embryo 
development.  
 395 
Effect of exposure of COCs to native OSFs during IVM on cryo-survival 
of blastocysts 
With respect to cryopreserved blastocysts, the blastocyst re-expansion rate 
post-vitrification/warming (normal morphology of blastocysts) did not differ 
significantly from control for blastocysts derived from COCs exposed to native 400 
OSFs (COCs+DOs at 3h+FSH+CC; Table 9). Therefore exposure of COCs to 
native OSFs did not measurably alter the cryotolerance of blastocysts.  
 
Effect of exposure of COCs to native OSFs on pregnancy rates and fetal 
outcomes  405 
After 2 h of warming, the morphologically normal blastocysts were transferred 
into pseudo pregnant recipients. There was no difference in implantation rates 
between the control and treatment group (COCs co-cultured with DOs 
[3h+FSH+CC]). However, the proportion of fetuses that developed to day 17 
per implantation site, from COCs co-cultured with native OSFs, was more 410 
than double that of the control (21% vs 48%, P < 0.05, Fig. 3). Moreover, 
based on gross morphological criteria, those fetuses were normal, with no 
significant differences between treatments in fetal or placental weight or fetal 




Our results show that treatment of COCs during IVM with native OSFs, 
enhances oocyte quality, as measured by subsequent embryo cleavage, 
blastocyst and fetal survival rates. These results are supported by previous 420 
studies which have shown that exogenous native OSFs (obtained by co-
culture with DOs), when used as supplements in oocyte IVM, significantly 
improve embryo development in cattle [20, 46, 47], pigs [48] and goats [45]. In 
contrast, addition of recombinant mature homodimers of GDF9 and/or BMP15 
(R&D Systems) in IVM media did not improve mouse embryo development 425 
(current study). However, previous results from our laboratory using a 
complex of pro- and mature-domains of GDF9 and BMP15 (pro-mature 
protein) showed a  positive effect on bovine as [12, 46, 47] well as mouse [49] 
oocyte developmental competence.   
From this study, we suggest that there are a number of factors which 430 
influence the capacity of exogenous OSFs to improve mouse embryo and 
fetal development post-IVM namely; the form of recombinant OSFs, the 
capacity of cumulus cells and FSH to regulate native OSF production, and the 
temporally regulated potency of the native OSF pool. Supplementation of IVM 
with OSFs has the potential to dramatically improve the efficiency of IVM and 435 
therefore its applicability in human and veterinary clinics [2], as we saw more 
than a doubling in fetal yield using this approach. However, this was only 
achieved using native and not recombinant OSFs, and while this illustrates the 
principal clearly, co-culture with denuded oocytes is not practical in a clinical 
scenario. Even though the exact identity of growth factors secreted by 440 
denuded oocytes in vitro remains poorly characterised, the principal OSFs are 
thought to be GDF9, BMP15, BMP6 fibroblast growth factor 8 (FGF8) and 
FGF10, with widely differing roles for individual growth factors between 
species [11, 26, 28-30, 41, 42, 52, 53]. Notably, the only commercially 
available recombinant preparations of GDF9 and BMP15 produced in 445 
mammalian cells, had no effect on post-IVM embryo development, despite the 
extensive dose range tested. By contrast, recombinant FGF10 added during 
bovine IVM enhances subsequent embryo development [52]. We hypothesize 
that the failure of these preparations of GDF9 and BMP15 to improve mouse 
IVM is because these proteins are supplied as isolated homodimers of their 450 
mature regions, lacking their prodomains. For the same reason we would 
predict that the GDF9 and BMP15 preparations produced in E.coli would be 
ineffective in IVM. GDF9 and BMP15 are likely to form a heterodimer, 
although so far the production of a recombinant preparation has proved 
controversial [55, 56] and it has not yet been tested in IVM. 455 
When full length recombinant GDF9 and BMP15 are expressed in 
mammalian cells such as human embryonic kidney 293H cells, the proteins 
are processed (pro and mature domains are proteolytically cleaved) and 
secreted into the medium as dimers or monomers of pro- and mature regions, 
that are non-covalently bound as pro-mature complexes [36]. Our in-house 460 
produced GDF9 and BMP15 preparations [41, 54], which contain both the pro- 
and mature domains, when added to IVM, significantly improve the quality of 
the blastocysts generated (as measured by ICM cell number) and thus 
improve fetal survival rates in mouse [49], as well as increase embryo 
development in cattle [12, 46, 47].   465 
The current results demonstrated that blastocyst development and fetal 
survival rates were further improved when COCs were co-cultured with DOs 
from 3 h (versus control), if those DOs were matured as COCs for the first 3 
hours in the presence of FSH, then subsequently denuded and added to IVM. 
This result supports previous findings in bovine IVM oocytes, which suggested 470 
a temporal effect on secretion of OSFs [46].  It has been demonstrated that 
even a short exposure of COCs to FSH significantly increases subsequent 
bovine blastocyst development, via protein kinase C activation [23]. Hence, 
the FSH-treated CCs may in some manner improve the quantity and/or quality 
of factors which are secreted by the resultant DO. During the 3 h maturation, 475 
the oocyte and cumulus cells communicate with each other through gap 
junctional communication and via paracrine factors, which presumably 
provides enough time for the oocyte to obtain the beneficial effect of FSH 
through the receptors in cumulus cells.  This effect may be mediated more by 
paracrine factors rather than gap junctional communication. After meiotic 480 
resumption, gap junctional communication between the oocyte and cumulus 
cells is lost [18]. The action of OSFs can be observed even without direct 
contact between cumulus cells and oocytes, suggesting that they are acting in 
a paracrine manner [6].  In the present study, the cleavage rate of mouse DOs 
post co-culture with COCs was significantly higher compared to DOs cultured 485 
alone (result not shown).  In cattle, the developmental competence of DOs co-
cultured with COCs is significantly improved compared to DOs cultured alone 
[20, 47]. 
Based on the notable improvement in oocyte developmental 
competence from the 3h+FSH+CC group, we anticipated that COCs matured 490 
first for 3 h in medium containing FSH would produce different quantities 
and/or forms of GDF9, compared to oocytes denuded at 0 h. However, 
unfortunately we were unable to detect any GDF9 in oocyte-conditioned 
medium, unlike the recent study by Lin et al (2012). This may be due to our 
oocyte-conditioning medium procedures or the western blot being 495 
insufficiently sensitive to detect actual secreted forms.  Also, we could not 
observe any effect of the 3 h pre-culture with FSH treated cumulus cells on 
the GDF9 produced within the oocyte. It showed that there was no difference 
in the amount or the proportion of either the pro-protein or the mature form of 
GDF9 in DOs at 0 h or 3 h. While GDF9 is the principal OSF produced by 500 
mouse oocytes [25, 41], other OSFs such as BMP15 [57], BMP6 [53], FGF10 
[52] and FGF8 [11]. may be processed and interact differently in DOs at 0 h 
and 3 h. 
Overall, we have shown that there is an obvious advantage to 
treatment of COCs with exogenous OSFs during IVM. Mouse exogenous 505 
OSFs did not affect oocyte nuclear maturation, in contrast with bovine oocytes 
matured in vitro, where co-culture with DOs improves nuclear maturation [20]. 
Clearly exogenous OSFs have major effects on key aspects governing the 
developmental program of oocytes, although it is not yet clear how and by 
which exact mechanisms this is achieved. Other groups have shown that 510 
native OSFs play a significant role in; the activity of hyaluronic acid synthase 2 
(HAS2), which correlates with mucification and expansion of CCs [13], 
increased GPX1 gene expression (related to the production of glutathione 
peroxidise as an antioxidant in oocytes), and enhanced expression of 
steroidogenic acute regulatory protein (STAR), which contributes to oocyte 515 
nuclear and cytoplasmic maturation [20]. Bovine oocytes matured with the 
mature form of BMP15 showed a significant increase in glucose uptake [9], 
and those matured with pro-mature BMP15  exhibited increased oxidative 
phosphorylation activity in the oocyte [12].  
The results of this current study confirm that OSFs notably improve 520 
embryo development and fetal survival in mice, and extend this knowledge by 
demonstrating for the first time that the effect of OSFs on mouse oocytes 
depends on timing, presence of FSH and cumulus cells. The observation that 
recombinant GDF9 and BMP15 in their mature form do not improve mouse 
embryo development leads us to the conclusion that the mature forms of 525 
those growth factors is not the functional form that improves the quality of IVM 
mouse oocytes.  The beneficial effect of native OSFs on oocyte quality and 
subsequent embryo development can be applied in the veterinary clinic; 
however, application of co-culture of COCs with DOs is not possible in human 
IVF clinics since it is unethical and not feasible to generate supernumerary 530 
DOs simply for OSF supplementation of media. Thus, the next step is to 
identify and purify the proteins that are secreted by oocytes, such as GDF9 
and BMP15, into a functional form that can be added into IVM medium, to 
improve the quality of IVM oocytes and subsequent embryo development and 
pregnancy rates.   535 
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(a) Schematic illustration of methods of producing native OSFs based on pretreatment of 
oocytes with and without cumulus cells and FSH 
Intact COCs cultured for 3 h in separate IVM medium containing FSH. After 3 h, COCs 
were denuded of CCs and the resultant DOs were then co-cultured with a separate cohort 
of COCs + FSH for 14-15 h, before the COCs underwent standard IVF and embryo culture 
(3h+FSH+CC) (b) COCs pre-cultured for 3 h in separate IVM medium without FSH, before 
denuding and co-cultured with a separate cohort of COCs + FSH for 14-15 h (3h-
FSH+CC) (c) COCs were denuded at 0 h and then pre-cultured for 3 h in separate IVM 
medium containing FSH, then these DOs were co-cultured with a separate cohort of COCs 
+ FSH for 14-15 h (3h+FSH-CC)  
 
Fig. 2 
(a) GDF9 Western blot comparison of denuded oocyte (DO) extracts at 0h and 3h 
(3h+FSH+CC) of pretreatment. mGDF9 refers to recombinant mGDF9 standard. Blank 
refers to DO sample in the absence of the GDF9 primary antibody. The 65kDa band 
corresponds to the unprocessed GDF9 pro-protein while the 17kDa band corresponds to 
the mature domain. The 90 kDa-180 kDa bands seen in all samples are attributed to the 
non-specific presence of biotinylated proteins in the cell extracts  
(b) Quantitative analysis of Western blot denuded oocyte extracts at 0 and 3h 
(3h+FSH+CC) of pretreatment from 5 separate experiments. The Western blot image was 
quantified using BioRad ChemiDoc MP system and analysed using Image J software 
(Biorad)   
 
Fig. 3 
Effect of treatment with native OSFs during IVM on subsequent pregnancy outcomes.  
Blastocysts were derived from standard IVM (control) or from COCs exposed to native 
OSFs during IVM (COC+DO; 3h+FSH+CC pretreatment). Control and treatment 
blastocysts were vitrified on day 6 and then later warmed and transferred to pseudo 
pregnant recipients. Six control and six treatment blastocysts were transferred into each 
uterine horn of a recipient (n=8). Pregnancy outcomes were analysed on day 17. 
Implantation rate; implantation sites/embryos transferred (n = 48 embryos 
transferred/treatment). Fetal yield; day 17 fetuses/implantation sites
       
 
 







COC + DO 
 
 































20 COCs were cultured in 50 µl IVM drops 
 
20 COCs were cultured with 50 DOs in 50 µl IVM drops. DOs were 
added at 0 h at the GVBD stage.  
 
20 COCs were cultured with 50 DOs in 50 µl IVM drops. DOs were 
added at 0 h at the GV stage, as IBMX was present in the handling 
medium and during denuding.  
 
COCs were pre-cultured for 3 h in separate IVM medium containing 
FSH. After 3 h, these COCs were denuded and 50 resultant DOs were 
then co-cultured with 20 COCs for another 14-15 h (Fig. 1a). 
 
COCs were pre-cultured for 3 h in separate IVM medium without FSH, 
before denuding and co-culture with 20 COCs for another 14-15 h (Fig. 
1b). 
 
COCs were denuded at 0 h and then cultured for 3 h as DOs in separate 
IVM medium containing FSH, then 50 resultant DOs were co-cultured 





Table 2 Effect of native OSFs during IVM on subsequent embryo development 
 
Treatments Number of 
oocytes 
Cleavage1  Blastocyst  
on day 52 
Blastocyst 
on day 63 
Hatching  
blastocyst  
on day 64 
ICM5 TE5 TCN5 
Control  224 90.6 ± 1.8a 52.8 ± 8.9 77.3 ± 4.6 58.8 ± 8.6 18.5 ± 0.8a 55.8 ± 2.1 74.3 ± 2.6 
COC + DO6  233 96.1 ± 0.8b 60.1 ± 4.9 74.3 ± 2.4 68.0 ± 1.9 25.3 ± 1.5b 55.5 ± 2.5 80.8 ± 3.5 
Values with different superscripts within a column are statistically different (P < 0.05) 
Data are presented as means ± SEM of 4 replicate experiments. Each replicate experiment consisted of 53-60 oocytes.  
1 Percentage of cleaved embryos per total oocytes  
2 Percentage of blastocysts generated 96-100 h post-fertilization per cleaved embryo 
3 Percentage of blastocysts generated 100-125 h post-fertilization per cleaved embryo 
4 Percentage of hatching blastocysts generated 100-125 h post fertilization per cleaved embryo 
5 Mean blastocyst cell numbers following differential staining of 16 – 18 blastocysts  
















on day 63 













82.9 ± 3.3 
74.6 ± 5.2 
74.8 ± 9.6 
86.1 ± 4.7 
81.7 ± 4.4 
72.6 ± 8.9 
82.6 ± 7.8 
82.5 ± 8.3 
62.6 ± 8.6 
61.8 ± 8.9 
59.1 ± 7.6 
64.3 ± 7.1 
16.0 ± 0.8 
16.8 ± 1.1 
16.7 ± 0.9 
17.9 ± 0.7 
53.0 ± 2.4 
54.2 ± 3.6 
49.2 ± 2.6 
56.8 ± 3.5 
69.0 ± 2.8 
71.0 ± 4.4 
65.9 ± 3.3 
74.8 ± 3.9 
Data are presented as means ± SEM of 5 replicate experiments. Each replicate experiment consisted of 10-50 oocytes. 
1 Percentage of cleaved embryos per total oocytes  
2 Percentage of blastocysts generated 100-125 h post-fertilization per cleaved embryo 
3 Percentage of hatching blastocysts generated 100-125 h post fertilization per cleaved embryo 
4 Mean blastocyst cell numbers following differential staining of 28 – 51 blastocysts  
 










on day 63 













66.6 ± 8.6 
77.7 ± 4.7 
75.8 ± 8.5 
76.3 ± 7.1 
64.8 ± 8.0 
56.4 ± 8.8 
65.1 ± 7.9 
63.4 ± 8.1 
44.3 ± 8.2 
36.5 ± 9.5 
45.0 ± 9.1 
43.1 ± 8.8 
16.2 ± 1.0 
16.4 ± 0.7 
17.6 ± 1.1 
18.9 ± 0.8 
50.7 ± 2.8 
48.3 ± 2.4 
49.1 ± 2.4 
55.1 ± 2.1 
66.9 ± 3.4 
64.8 ± 3.0 
66.7 ± 3.1 
74.0 ± 2.5 
Data are presented as means ± SEM of 7 replicate experiments. Each replicate experiment consisted of 14-75 oocytes. 
1Percentage of cleaved embryos per total oocytes 
2Percentage of blastocysts generated 100-125 h post-fertilization per cleaved embryo 
3Percentage of hatching blastocysts generated 100-125 h post fertilization per cleaved embryo 
4Number of blastocysts staining in each treatment group 38-47  
 
 
Table 5 Effect of graded doses of GDF9 and BMP15 during IVM on subsequent embryo development  
 






on day 62 
Hatching 
blastocyst  
on day 63 
ICM4 TE4 TCN4 
Control 
BMP15 + GDF9 
BMP15 + GDF9 
BMP15 + GDF9 
0 + 0 
50 + 50 
100 + 100 





92.0 ± 1.3 
91.5 ± 2.7 
93.2 ± 0.4 
89.7 ± 5.2 
85.4 ± 5.7 
82.6 ± 9.5 
78.6 ± 10.8 
72.3 ± 7.1 
84.2 ± 6.9 
80.5 ± 11.5 
75.2 ± 11.3 
67.0 ± 7.6 
12.9 ± 0.8 
12.7 ± 0.7 
12.9 ± 1.0 
11.8 ± 1.0 
42.8 ± 1.7 
43.5 ± 2.6 
37.9 ± 2.1 
45.5 ± 2.1 
55.7 ± 1.9 
56.2 ± 2.9 
50.8 ± 2.1 
57.3 ± 2.7 
Data are presented as means ± SEM of 3 replicate experiments. Each replicate experiment consisted of 12-40 oocytes. 
1Percentage of cleaved embryos per total oocytes 
2Percentage of blastocysts generated 100-125 h post-fertilization per cleaved embryo 
3Percentage of hatching blastocysts generated 100-125 h post fertilization per cleaved embryo 







Table 6 Effects of exogenous native OSFs during IVM on subsequent embryo development  
Values with different superscripts within a column are statistically different (P < 0.05) 
Data are presented as means ± SEM of 4 replicate experiments. Each replicate experiment consisted of 37-40 oocytes. 
1See Figure 1 and Table 1 for explanation of experimental design 
2Percentage of cleaved embryos per total oocytes  
3Percentage of blastocysts generated 96-100 h post-fertilization per cleaved embryo 
4 Percentage of blastocysts generated 100-125 h post-fertilization per cleaved embryo 
5 Percentage of hatching blastocysts generated 100-125 h post fertilization per cleaved embryo 
6 Mean blastocyst cell numbers following differential staining of 13-22 blastocysts  
 





Cleavage2 Blastocyst  
on day 53 
Blastocyst  
on day 64 
Hatching  
blastocyst 
 on day 65 
ICM6 TE6 TCN6 
Control N/A 152 87.5 ± 1.6a 52.2 ± 7.2 67.4 ± 6.0a 53.3 ± 5.6a 18.7 ± 1.9a 51.1 ± 3.4 69.8 ± 4.3 
COC + DO  0h [GV] 155 95.5 ± 2.2b 57.5 ± 2.6 77.2 ± 4.4a,b 66.9 ± 2.8a,b 22.0 ± 1.7a,b 52.4 ± 2.4 74.4 ± 3.5 
COC + DO  3h+FSH+CCs 153 94.8 ± 1.1a,b 65.5 ± 1.7 83.4 ± 2.6b 74.5 ± 2.8b 24.8 ± 1.3b 55.7 ± 2.7 80.5 ± 3.4 
Table 7 Effect of native OSFs added at 3 hours on oocyte nuclear maturation 
 
Treatments Pre-treatment of OSFs1 Maturation time (h) n MII oocytes (%) 
Control  
 
COC + DO  
N/A 
 













Data are presented as means of 3 replicate experiments. Each replicate experiment consisted of 33-39 oocytes. 







Table 8 Effects of cumulus cells and FSH on native OSF efficacy at enhancing post-IVM embryo development  
Values with different superscripts within a column are statistically different (P < 0.05) 
Data are presented as means ± SEM of 5 replicate experiments. Each replicate experiment consisted of 36-39 oocytes. 
1See Figure 1 and Table 1 for explanation of experimental design 
2Percentage of cleaved embryos per total oocytes  
3Percentage of blastocysts generated 96-100 h post-fertilization per cleaved embryo 
4 Percentage of blastocysts generated 100-125 h post-fertilization per cleaved embryo 
5 Percentage of hatching blastocysts generated 100-125 h post fertilization per cleaved embryo 




Treatments          Pre-treatment  
         OSFs1 
Number of 
oocytes 
Cleavage2 Blastocyst  
on day 53 
Blastocyst  
on day 64 
Hatching  
Blastocyst 
 on d65 
ICM6 TE6 TCN6 
Control N/A 192 92.7 ± 2.9 52.5 ± 3.4a 76.6 ± 3.0a 60.8 ± 3.3 11.9 ± 0.6a 43.1 ± 2.2 55.0 ± 2.4 
COC + DO  3h+FSH+CCs 191 93.6 ± 1.9 65.2 ± 5.6b 83.2 ± 2.0a,b 69.0 ± 3.4 13.8 ± 0.5b 43.6 ± 1.5 57.4 ± 1.6 
COC + DO  3h-FSH+CCs 190 94.7 ± 1.9 61.0 ± 3.6a,b 79.5 ± 2.5a,b 66.7 ± 4.0 11.7 ± 0.5a 46.4 ± 1.9 58.2 ± 2.0 
COC + DO  3h+FSH-CCs 191 93.7 ± 2.5 63.8 ± 3.5a,b 86.2 ± 2.9b 70.4 ± 2.7 12.2 ± 0.7a,b 44.1 ± 2.0 56.3 ± 2.4 
Table 9 Effect of native OSFs during IVM on survival rate post-warming of blastocysts 
 
Treatments Pre-treatment OSFs1 Numbers of blastocysts Normal (%) Abnormal (%) 
Control N/A 90 73 (81.1) 17 (18.9) 
COC + DO 3h+FSH+CC 92 74 (80.4) 18 (19.6) 
Data are presented as means of 6 replicate experiments. Each replicate experiment consisted of 10-19 blastocysts. 
1See Figure 1 and Table 1 for explanation of experimental design  
 
 
Table 10 Effect of native OSFs during IVM on subsequent fetal and placental weight and crown-rump length 
 
Treatments Pre-treatment OSFs1 Placental weight (g) Fetal weight (g) Crown to rump length 
(mm) 
Control N/A 0.2 ± 0.01 1.8 ± 0.1 24.5 ± 1.9 
 COC + DO 3h+FSH+CC 0.2 ± 0.01 1.7 ± 0.1 25.6 ± 0.8 
Data are presented as means ± SEM of 6 and 13 fetuses (control and treatment, respectively) from 8 recipients.  
1See Figure 1 and Table 1 for explanation of experimental design  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
